D-0478-2023 Class II Terminated

Recalled by Direct Rx — Dawsonville, GA

FDA drug recall D-0478-2023 was initiated by Direct Rx on Mar 13, 2023 and is designated Class II. Reason for recall: cGMP deviations The recall status is terminated (terminated Jun 17, 2024). Affected quantity: 9 bottles.

Recall details

Product Type
Drugs
Report Date
Apr 5, 2023
Initiation Date
Mar 13, 2023
Termination Date
Jun 17, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
9 bottles

Product description

Ropinirole, USP, 0.25 mg Tablets, Rx Only, Packaged as a 30-count bottle, NDC 72189-0364-30; Packaged and Distributed By: Direct Rx, Dawsonville, GA 30534

Reason for recall

cGMP deviations

Distribution pattern

Nationwide in the USA

Code information

Lot, expiry: 21JU2210, exp 7/31/23

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0478-2023
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0478-2023. Report a data issue: hello@regdatalab.com.